| |
| Obesity and Diabetes care |
|
 93.66 % |
of total Revenue |
| Obesity and Diabetes care segments |
|
93.66 % |
of total Revenue |
| Rare disease |
|
6.34 % |
of total Revenue |
| Rare disease segments |
|
6.34 % |
of total Revenue |
| USA |
|
56.03 % |
of total Revenue |
| Obesity and Diabetes care total |
|
93.66 % |
of total Revenue |
| Rare disease total |
|
6.34 % |
of total Revenue |
| Total GLP-1 Obesity and Diabetes care total |
|
49.25 % |
of total Revenue |
| Ozempic Obesity and Diabetes care total |
|
41.12 % |
of total Revenue |
| Rybelsus Obesity and Diabetes care total |
|
7.15 % |
of total Revenue |
| Victoza Obesity and Diabetes care total |
|
0.98 % |
of total Revenue |
| Total insulin Obesity and Diabetes care total |
|
17.19 % |
of total Revenue |
| Long-acting insulin Obesity and Diabetes care total |
|
6.07 % |
of total Revenue |
| Awigli Obesity and Diabetes care total |
|
0.13 % |
of total Revenue |
| Tresiba Obesity and Diabetes care total |
|
3.9 % |
of total Revenue |
| Xultophy Obesity and Diabetes care total |
|
1.49 % |
of total Revenue |
| Levemir Obesity and Diabetes care total |
|
0.54 % |
of total Revenue |
| Premix insulin Obesity and Diabetes care total |
|
3.34 % |
of total Revenue |
| Ryzodeg Obesity and Diabetes care total |
|
1.74 % |
of total Revenue |
| NovoMix Obesity and Diabetes care total |
|
1.6 % |
of total Revenue |
| Fast-acting insulin Obesity and Diabetes care total |
|
6.01 % |
of total Revenue |
| Fiasp Obesity and Diabetes care total |
|
0.91 % |
of total Revenue |
| NovoRapid Obesity and Diabetes care total |
|
5.1 % |
of total Revenue |
| Human insulin Obesity and Diabetes care total |
|
1.77 % |
of total Revenue |
| Other Diabetes care Obesity and Diabetes care total |
|
0.57 % |
of total Revenue |
| Total Diabetes care Obesity and Diabetes care total |
|
67.01 % |
of total Revenue |
| Total Obesity care Obesity and Diabetes care total |
|
26.64 % |
of total Revenue |
| Wegovy Obesity and Diabetes care total |
|
25.6 % |
of total Revenue |
| Saxenda Obesity and Diabetes care total |
|
1.05 % |
of total Revenue |
| Rare blood disorders Rare disease total |
|
3.87 % |
of total Revenue |
| Haemophilia A Rare disease total |
|
0.78 % |
of total Revenue |
| Haemophilia B Rare disease total |
|
0.46 % |
of total Revenue |
| NovoSeven Rare disease total |
|
2.37 % |
of total Revenue |
| Rare endocrine disorders Rare disease total |
|
1.93 % |
of total Revenue |
| Other Rare disease Rare disease total |
|
0.55 % |
of total Revenue |
| International Operations |
|
43.97 % |
of total Revenue |
| International Operations Obesity and Diabetes care total |
|
40.45 % |
of total Revenue |
| International Operations Rare disease total |
|
3.52 % |
of total Revenue |
| International Operations Total GLP-1 Obesity and Diabetes care total |
|
17.61 % |
of total Revenue |
| International Operations Ozempic Obesity and Diabetes care total |
|
12.5 % |
of total Revenue |
| International Operations Rybelsus Obesity and Diabetes care total |
|
4.29 % |
of total Revenue |
| International Operations Victoza Obesity and Diabetes care total |
|
0.82 % |
of total Revenue |
| International Operations Total insulin Obesity and Diabetes care total |
|
12.26 % |
of total Revenue |
| International Operations Long-acting insulin Obesity and Diabetes care total |
|
4.45 % |
of total Revenue |
| International Operations Awigli Obesity and Diabetes care total |
|
0.13 % |
of total Revenue |
| International Operations Tresiba Obesity and Diabetes care total |
|
2.38 % |
of total Revenue |
| International Operations Xultophy Obesity and Diabetes care total |
|
1.4 % |
of total Revenue |
| International Operations Levemir Obesity and Diabetes care total |
|
0.54 % |
of total Revenue |
| International Operations Premix insulin Obesity and Diabetes care total |
|
3.15 % |
of total Revenue |
| International Operations Ryzodeg Obesity and Diabetes care total |
|
1.74 % |
of total Revenue |
| International Operations NovoMix Obesity and Diabetes care total |
|
1.41 % |
of total Revenue |
| International Operations Fast-acting insulin Obesity and Diabetes care total |
|
3.34 % |
of total Revenue |
| International Operations Fiasp Obesity and Diabetes care total |
|
0.56 % |
of total Revenue |
| International Operations NovoRapid Obesity and Diabetes care total |
|
2.78 % |
of total Revenue |
| International Operations Human insulin Obesity and Diabetes care total |
|
1.32 % |
of total Revenue |
| International Operations Other Diabetes care Obesity and Diabetes care total |
|
0.53 % |
of total Revenue |
| International Operations Total Diabetes care Obesity and Diabetes care total |
|
30.4 % |
of total Revenue |
| International Operations Total Obesity care Obesity and Diabetes care total |
|
10.05 % |
of total Revenue |
| International Operations Wegovy Obesity and Diabetes care total |
|
9.09 % |
of total Revenue |
| International Operations Saxenda Obesity and Diabetes care total |
|
0.96 % |
of total Revenue |
| International Operations Rare blood disorders Rare disease total |
|
2.27 % |
of total Revenue |
| International Operations Haemophilia A Rare disease total |
|
0.65 % |
of total Revenue |
| International Operations Haemophilia B Rare disease total |
|
0.28 % |
of total Revenue |
| International Operations NovoSeven Rare disease total |
|
1.24 % |
of total Revenue |
| International Operations Rare endocrine disorders Rare disease total |
|
0.8 % |
of total Revenue |
| International Operations Other Rare disease Rare disease total |
|
0.44 % |
of total Revenue |
| EUCAN |
|
21.38 % |
of total Revenue |
| EUCAN Obesity and Diabetes care total |
|
19.67 % |
of total Revenue |
| EUCAN Rare disease total |
|
1.72 % |
of total Revenue |
| EUCAN Total GLP-1 Obesity and Diabetes care total |
|
9.88 % |
of total Revenue |
| EUCAN Ozempic Obesity and Diabetes care total |
|
7.37 % |
of total Revenue |
| EUCAN Rybelsus Obesity and Diabetes care total |
|
2.29 % |
of total Revenue |
| EUCAN Victoza Obesity and Diabetes care total |
|
0.22 % |
of total Revenue |
| EUCAN Total insulin Obesity and Diabetes care total |
|
4.18 % |
of total Revenue |
| EUCAN Long-acting insulin Obesity and Diabetes care total |
|
2.02 % |
of total Revenue |
| EUCAN Awigli Obesity and Diabetes care total |
|
0.03 % |
of total Revenue |
| EUCAN Tresiba Obesity and Diabetes care total |
|
1.15 % |
of total Revenue |
| EUCAN Xultophy Obesity and Diabetes care total |
|
0.6 % |
of total Revenue |
| EUCAN Levemir Obesity and Diabetes care total |
|
0.23 % |
of total Revenue |
| EUCAN Premix insulin Obesity and Diabetes care total |
|
0.3 % |
of total Revenue |
| EUCAN Ryzodeg Obesity and Diabetes care total |
|
0.07 % |
of total Revenue |
| EUCAN NovoMix Obesity and Diabetes care total |
|
0.23 % |
of total Revenue |
| EUCAN Fast-acting insulin Obesity and Diabetes care total |
|
1.63 % |
of total Revenue |
| EUCAN Fiasp Obesity and Diabetes care total |
|
0.43 % |
of total Revenue |
| EUCAN NovoRapid Obesity and Diabetes care total |
|
1.2 % |
of total Revenue |
| EUCAN Human insulin Obesity and Diabetes care total |
|
0.23 % |
of total Revenue |
| EUCAN Other Diabetes care Obesity and Diabetes care total |
|
0.17 % |
of total Revenue |
| EUCAN Total Diabetes care Obesity and Diabetes care total |
|
14.22 % |
of total Revenue |
| EUCAN Total Obesity care Obesity and Diabetes care total |
|
5.44 % |
of total Revenue |
| EUCAN Wegovy Obesity and Diabetes care total |
|
4.98 % |
of total Revenue |
| EUCAN Saxenda Obesity and Diabetes care total |
|
0.47 % |
of total Revenue |
| EUCAN Rare blood disorders Rare disease total |
|
1.08 % |
of total Revenue |
| EUCAN Haemophilia A Rare disease total |
|
0.32 % |
of total Revenue |
| EUCAN Haemophilia B Rare disease total |
|
0.2 % |
of total Revenue |
| EUCAN NovoSeven Rare disease total |
|
0.53 % |
of total Revenue |
| EUCAN Rare endocrine disorders Rare disease total |
|
0.32 % |
of total Revenue |
| EUCAN Other Rare disease Rare disease total |
|
0.31 % |
of total Revenue |
| Emerging Markets |
|
9.85 % |
of total Revenue |
| Emerging Markets Obesity and Diabetes care total |
|
8.96 % |
of total Revenue |
| Emerging Markets Rare disease total |
|
0.89 % |
of total Revenue |
| Emerging Markets Total GLP-1 Obesity and Diabetes care total |
|
3.35 % |
of total Revenue |
| Emerging Markets Ozempic Obesity and Diabetes care total |
|
2.34 % |
of total Revenue |
| Emerging Markets Rybelsus Obesity and Diabetes care total |
|
0.67 % |
of total Revenue |
| Emerging Markets Victoza Obesity and Diabetes care total |
|
0.34 % |
of total Revenue |
| Emerging Markets Total insulin Obesity and Diabetes care total |
|
3.15 % |
of total Revenue |
| Emerging Markets Long-acting insulin Obesity and Diabetes care total |
|
0.96 % |
of total Revenue |
| Emerging Markets Tresiba Obesity and Diabetes care total |
|
0.64 % |
of total Revenue |
| Emerging Markets Xultophy Obesity and Diabetes care total |
|
0.1 % |
of total Revenue |
| Emerging Markets Levemir Obesity and Diabetes care total |
|
0.22 % |
of total Revenue |
| Emerging Markets Premix insulin Obesity and Diabetes care total |
|
0.66 % |
of total Revenue |
| Emerging Markets Ryzodeg Obesity and Diabetes care total |
|
0.28 % |
of total Revenue |
| Emerging Markets NovoMix Obesity and Diabetes care total |
|
0.38 % |
of total Revenue |
| Emerging Markets Fast-acting insulin Obesity and Diabetes care total |
|
0.94 % |
of total Revenue |
| Emerging Markets Fiasp Obesity and Diabetes care total |
|
0.07 % |
of total Revenue |
| Emerging Markets NovoRapid Obesity and Diabetes care total |
|
0.87 % |
of total Revenue |
| Emerging Markets Human insulin Obesity and Diabetes care total |
|
0.59 % |
of total Revenue |
| Emerging Markets Other Diabetes care Obesity and Diabetes care total |
|
0.08 % |
of total Revenue |
| Emerging Markets Total Diabetes care Obesity and Diabetes care total |
|
6.59 % |
of total Revenue |
| Emerging Markets Total Obesity care Obesity and Diabetes care total |
|
2.37 % |
of total Revenue |
| Emerging Markets Wegovy Obesity and Diabetes care total |
|
1.97 % |
of total Revenue |
| Emerging Markets Saxenda Obesity and Diabetes care total |
|
0.4 % |
of total Revenue |
| Emerging Markets Rare blood disorders Rare disease total |
|
0.63 % |
of total Revenue |
| Emerging Markets Haemophilia A Rare disease total |
|
0.13 % |
of total Revenue |
| Emerging Markets Haemophilia B Rare disease total |
|
0.03 % |
of total Revenue |
| Emerging Markets NovoSeven Rare disease total |
|
0.46 % |
of total Revenue |
| Emerging Markets Rare endocrine disorders Rare disease total |
|
0.19 % |
of total Revenue |
| Emerging Markets Other Rare disease Rare disease total |
|
0.07 % |
of total Revenue |
| APAC |
|
6.7 % |
of total Revenue |
| APAC Obesity and Diabetes care total |
|
6.02 % |
of total Revenue |
| APAC Rare disease total |
|
0.68 % |
of total Revenue |
| APAC Total GLP-1 Obesity and Diabetes care total |
|
2.24 % |
of total Revenue |
| APAC Ozempic Obesity and Diabetes care total |
|
1.04 % |
of total Revenue |
| APAC Rybelsus Obesity and Diabetes care total |
|
1.14 % |
of total Revenue |
| APAC Victoza Obesity and Diabetes care total |
|
0.07 % |
of total Revenue |
| APAC Total insulin Obesity and Diabetes care total |
|
1.73 % |
of total Revenue |
| APAC Long-acting insulin Obesity and Diabetes care total |
|
0.43 % |
of total Revenue |
| APAC Awigli Obesity and Diabetes care total |
|
0.01 % |
of total Revenue |
| APAC Tresiba Obesity and Diabetes care total |
|
0.27 % |
of total Revenue |
| APAC Xultophy Obesity and Diabetes care total |
|
0.12 % |
of total Revenue |
| APAC Levemir Obesity and Diabetes care total |
|
0.03 % |
of total Revenue |
| APAC Premix insulin Obesity and Diabetes care total |
|
0.68 % |
of total Revenue |
| APAC Ryzodeg Obesity and Diabetes care total |
|
0.43 % |
of total Revenue |
| APAC NovoMix Obesity and Diabetes care total |
|
0.26 % |
of total Revenue |
| APAC Fast-acting insulin Obesity and Diabetes care total |
|
0.36 % |
of total Revenue |
| APAC Fiasp Obesity and Diabetes care total |
|
0.07 % |
of total Revenue |
| APAC NovoRapid Obesity and Diabetes care total |
|
0.29 % |
of total Revenue |
| APAC Human insulin Obesity and Diabetes care total |
|
0.26 % |
of total Revenue |
| APAC Other Diabetes care Obesity and Diabetes care total |
|
0.09 % |
of total Revenue |
| APAC Total Diabetes care Obesity and Diabetes care total |
|
4.06 % |
of total Revenue |
| APAC Total Obesity care Obesity and Diabetes care total |
|
1.97 % |
of total Revenue |
| APAC Wegovy Obesity and Diabetes care total |
|
1.88 % |
of total Revenue |
| APAC Saxenda Obesity and Diabetes care total |
|
0.09 % |
of total Revenue |
| APAC Rare blood disorders Rare disease total |
|
0.34 % |
of total Revenue |
| APAC Haemophilia A Rare disease total |
|
0.08 % |
of total Revenue |
| APAC Haemophilia B Rare disease total |
|
0.05 % |
of total Revenue |
| APAC NovoSeven Rare disease total |
|
0.15 % |
of total Revenue |
| APAC Rare endocrine disorders Rare disease total |
|
0.28 % |
of total Revenue |
| APAC Other Rare disease Rare disease total |
|
0.06 % |
of total Revenue |
| Region China |
|
6.04 % |
of total Revenue |
| Region China Obesity and Diabetes care total |
|
5.8 % |
of total Revenue |
| Region China Rare disease total |
|
0.23 % |
of total Revenue |
| Region China Total GLP-1 Obesity and Diabetes care total |
|
2.14 % |
of total Revenue |
| Region China Ozempic Obesity and Diabetes care total |
|
1.75 % |
of total Revenue |
| Region China Rybelsus Obesity and Diabetes care total |
|
0.2 % |
of total Revenue |
| Region China Victoza Obesity and Diabetes care total |
|
0.19 % |
of total Revenue |
| Region China Total insulin Obesity and Diabetes care total |
|
3.2 % |
of total Revenue |
| Region China Long-acting insulin Obesity and Diabetes care total |
|
1.04 % |
of total Revenue |
| Region China Awigli Obesity and Diabetes care total |
|
0.09 % |
of total Revenue |
| Region China Tresiba Obesity and Diabetes care total |
|
0.31 % |
of total Revenue |
| Region China Xultophy Obesity and Diabetes care total |
|
0.58 % |
of total Revenue |
| Region China Levemir Obesity and Diabetes care total |
|
0.06 % |
of total Revenue |
| Region China Premix insulin Obesity and Diabetes care total |
|
1.51 % |
of total Revenue |
| Region China Ryzodeg Obesity and Diabetes care total |
|
0.96 % |
of total Revenue |
| Region China NovoMix Obesity and Diabetes care total |
|
0.55 % |
of total Revenue |
| Region China Fast-acting insulin Obesity and Diabetes care total |
|
0.42 % |
of total Revenue |
| Region China NovoRapid Obesity and Diabetes care total |
|
0.42 % |
of total Revenue |
| Region China Human insulin Obesity and Diabetes care total |
|
0.23 % |
of total Revenue |
| Region China Other Diabetes care Obesity and Diabetes care total |
|
0.19 % |
of total Revenue |
| Region China Total Diabetes care Obesity and Diabetes care total |
|
5.54 % |
of total Revenue |
| Region China Total Obesity care Obesity and Diabetes care total |
|
0.27 % |
of total Revenue |
| Region China Wegovy Obesity and Diabetes care total |
|
0.26 % |
of total Revenue |
| Region China Saxenda Obesity and Diabetes care total |
|
0.01 % |
of total Revenue |
| Region China Rare blood disorders Rare disease total |
|
0.23 % |
of total Revenue |
| Region China Haemophilia A Rare disease total |
|
0.12 % |
of total Revenue |
| Region China Haemophilia B Rare disease total |
|
0.01 % |
of total Revenue |
| Region China NovoSeven Rare disease total |
|
0.1 % |
of total Revenue |
| Region China Rare endocrine disorders Rare disease total |
|
0.01 % |
of total Revenue |
| Region China Other Rare disease Rare disease total |
|
0 % |
of total Revenue |
| USA Obesity and Diabetes care total |
|
53.2 % |
of total Revenue |
| USA Rare disease total |
|
2.83 % |
of total Revenue |
| USA Total GLP-1 Obesity and Diabetes care total |
|
31.63 % |
of total Revenue |
| USA Ozempic Obesity and Diabetes care total |
|
28.62 % |
of total Revenue |
| USA Rybelsus Obesity and Diabetes care total |
|
2.86 % |
of total Revenue |
| USA Victoza Obesity and Diabetes care total |
|
0.15 % |
of total Revenue |
| USA Total insulin Obesity and Diabetes care total |
|
4.93 % |
of total Revenue |
| USA Long-acting insulin Obesity and Diabetes care total |
|
1.62 % |
of total Revenue |
| USA Tresiba Obesity and Diabetes care total |
|
1.52 % |
of total Revenue |
| USA Xultophy Obesity and Diabetes care total |
|
0.1 % |
of total Revenue |
| USA Levemir Obesity and Diabetes care total |
|
0 % |
of total Revenue |
| USA Premix insulin Obesity and Diabetes care total |
|
0.18 % |
of total Revenue |
| USA NovoMix Obesity and Diabetes care total |
|
0.18 % |
of total Revenue |
| USA Fast-acting insulin Obesity and Diabetes care total |
|
2.67 % |
of total Revenue |
| USA Fiasp Obesity and Diabetes care total |
|
0.35 % |
of total Revenue |
| USA NovoRapid Obesity and Diabetes care total |
|
2.32 % |
of total Revenue |
| USA Human insulin Obesity and Diabetes care total |
|
0.46 % |
of total Revenue |
| USA Other Diabetes care Obesity and Diabetes care total |
|
0.04 % |
of total Revenue |
| USA Total Diabetes care Obesity and Diabetes care total |
|
36.61 % |
of total Revenue |
| USA Total Obesity care Obesity and Diabetes care total |
|
16.59 % |
of total Revenue |
| USA Wegovy Obesity and Diabetes care total |
|
16.51 % |
of total Revenue |
| USA Saxenda Obesity and Diabetes care total |
|
0.09 % |
of total Revenue |
| USA Rare blood disorders Rare disease total |
|
1.59 % |
of total Revenue |
| USA Haemophilia A Rare disease total |
|
0.13 % |
of total Revenue |
| USA Haemophilia B Rare disease total |
|
0.18 % |
of total Revenue |
| USA NovoSeven Rare disease total |
|
1.13 % |
of total Revenue |
| USA Rare endocrine disorders Rare disease total |
|
1.13 % |
of total Revenue |
| USA Other Rare disease Rare disease total |
|
0.11 % |
of total Revenue |
